Human primary fibroblasts perform similarly to MSCs in assays used to evaluate MSC safety and potency
Abstract
Cellular therapeutic agents may benefit trauma patients by modulating the immune response to injury, and by reducing inflammation and vascular leakage. Administration of allogeneic mesenchymal stromal cells (MSCs) shows some benefit in preclinical and clinical trials, but less testing has been performed with other cell types. Human primary fibroblasts (FBs) were compared to MSCs in assays designed to evaluate MSCs to determine if these assays actually evaluate properties unique to MSCs or whether related cell types perform similarly.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2019
- Source ID
- 10.1111/trf.15187
Entities
People
- Andrew P Cap
- Barbara A Christy
- Carolina Cantu
- Christi Salgado
- Christopher Delavan
- James A. Bynum
- Maryanne C. Herzig
Organizations
- Baylor University
- United States Army Medical Research and Development Command
- University of Texas Health Science Center at San Antonio
- University of Texas at San Antonio